Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.44 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9133303 | 0.92 | BAZ2B (0.54) | BAZ2BKDM4ERAB9AGAAKMT2A | |
| SCHEMBL9134544 | 0.83 | KMT2A (0.49) | KDM4ERAB9AGAAKMT2ANPC1 | |
| SCHEMBL4882425 | 0.82 | RIPK1 (0.50) | RAB9ANPC1RIPK1SMN1; SMN2MAPT | |
| SCHEMBL7860721 | 0.80 | RAB9A (0.73) | BAZ2BKDM4ERAB9AGAAKMT2A | |
| SCHEMBL9133647 | 0.78 | AURKA (0.57) | KMT2ARIPK1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL26849762 | 0.77 | RAB9A (0.56) | RAB9AKMT2ANPC1RIPK1ROCK1 | |
| SCHEMBL26847457 | 0.75 | RAB9A (0.67) | BAZ2BKDM4ERAB9AGAAKMT2A | |
| SCHEMBL9134106 | 0.75 | CHRNA7 (0.47) | RIPK1NPY5R | |
| SCHEMBL14825173 | 0.75 | POLB (0.56) | KDM4ERAB9AGAAKMT2ANPC1 | |
| SCHEMBL8568625 | 0.75 | BAZ2B (1.00) | BAZ2BKDM4ERAB9AGAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365571-A1 | COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS | NOVARTIS AG (CH) | 2023-11-16 | — | — | US | disclosed |
| US-20230365571-A1 | COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS | NOVARTIS AG (CH) | 2023-11-16 | — | — | US | disclosed |
| US-5464860-A | Antiepileptic agents | NOVAPHARME (FR) | 1995-11-07 | — | — | US | disclosed |
| US-5258397-A | FOR TREATMENT OF EPILEPSY; SIDE EFFECT REDUCTION | NOVAPHARME (FR) | 1993-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365571-A1 | COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS | SPPL2A, SPPL2B, BACE1 | BAZ2B 394/4885KDM4E 4701/4885RAB9A 4173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.